One-Shot gene therapy aims to replace monthly eye injections for vision loss
NCT ID NCT05657301
Summary
This early-stage study is testing the safety of a new gene therapy called KH631 for people with 'wet' age-related macular degeneration (AMD), a leading cause of vision loss. The therapy is designed as a one-time injection into the eye to help the body block a protein that causes harmful blood vessel growth, potentially reducing the need for frequent anti-VEGF injections. The study will enroll about 25 participants to find a safe dose and monitor them for side effects over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanghong Investigative Site
Phoenix, Arizona, 85016, United States
-
Kanghong Investigative Site
Lemont, Illinois, 60439, United States
-
Kanghong Investigative Site
Boston, Massachusetts, 02114, United States
-
Kanghong Investigative Site
Reno, Nevada, 89502, United States
-
Kanghong Investigative Site
Cherry Hill, New Jersey, 08034, United States
-
Kanghong Investigative Site
Germantown, Tennessee, 38138, United States
-
Kanghong Investigative Site
Dallas, Texas, 75231, United States
Conditions
Explore the condition pages connected to this study.